From the Journals

ICYMI: MRI-based treat-to-target approach offers no benefit for RA patients



Patients with RA in clinical remission who received an MRI-based treat-to-target strategy did not achieve superior disease activity remission rates (85% vs. 88%) or reduced radiographic progression (66% vs. 62%), compared with a conventional treat-to-target strategy, according to results of the Danish, 2-year, investigator-initiated, randomized, multicenter IMAGINE-RA trial published in JAMA (2019 Feb 5. doi: 10.1001/jama.2018.21362).

We covered this study at the 2018 European Congress of Rheumatology before it was published in the journal. Read the story at the link above.

Next Article: